Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  yttrium Y 90 ibritumomab tiuxetan
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 45 for your search:
Start Over
Zevalin-beam for Aggressive Lymphoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: Other
Protocol IDs: SHEBA-07-4466-AN-CTIL, NCT00491491
Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma That Has Relapsed After High-Dose Chemotherapy and Autologous Stem Cell Transplantation
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 19 and over
Sponsor: Other
Protocol IDs: 535-00, CDR0000069211, NCI-V02-1691, UNMC-535-00, NCT00031642
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02721, AMC-037, U01CA070019, CDR0000310158, NCT00064246
Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: Other
Protocol IDs: ID01-233, NCT00048737
Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 51 to 75
Sponsor: Other
Protocol IDs: CDR0000515982, KRDI-TUM-R-F-015-V-0030-I, EU-20633, NCT00397800
CpG 7909, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Treatment
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: LS0382, 703-04, MAYO-LS0382, MAYO-IRB-703-04, NCT00438880
Radioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: Other
Protocol IDs: 2005-002206-37, NCT00302757
Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 60
Sponsor: NCI, Other
Protocol IDs: 98153, P30CA033572, P01CA030206, CHNMC-98153, CDR0000574716, NCT00562978
Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: NU 02H8, 1346001, NU-0228-024, PCI-P-PCYC-0213, NCT00089284
Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: NU 05H9, STU00004871, NU-0522-060, MILLENNIUM-NU-05H9, NCT00372905
Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma
Phase: Phase II
Type: Supportive care, Treatment
Status: Closed
Age: 60 and over
Sponsor: NCI, Other
Protocol IDs: 02-090, MSKCC-02090, NCT00058422
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000304498, CALGB-50201, SWOG-C50201, ECOG-C50201, NCT00062114
S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: NCI, Other
Protocol IDs: CDR0000329864, U10CA032102, S0313, SWOG-S0313, NCT00070018
Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: ID01-541, NCT00038623
Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 04-251, NCT00119730
Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 65
Sponsor: Other
Protocol IDs: Z-BEAM, NCT00138086
Study to Evaluate the Efficacy of Rituximab in Combination With Low-dose Radiotherapy in Patients With Relapsed Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: Ritux plus TNI, NCT00147953
Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: Other
Protocol IDs: SCRI LYM 27, 106-P092, NCT00193505
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
Phase: Phase II
Type: Treatment
Status: Closed
Age: No age limit
Sponsor: Other
Protocol IDs: ID03-0287, NCI-2011-02453, NCT00290511
Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 64 and under
Sponsor: Other
Protocol IDs: AMC 2005-276, NCT00336843
The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: TH011101, NCT00440583
Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2005-0512, NCI-2012-01569, NCT00493467
Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 65 to 80
Sponsor: Other
Protocol IDs: CDR0000589530, CALACASS-3RCHOPZ, INCA-RECF0624, EUDRACT-2006-006179-19, CALACASS-2006/27, 3 R CHOP Z, NCT00690560
Start Over